Lupin Wins FDA Approval For Ranluspec Biosimilar To Lucentis

Lupin received U.S. FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, in both vial and pre-filled syringe formats. The approval covers the same 0.3 mg and 0.5 mg strengths as the reference product, expanding Lupin’s biosimilar portfolio in the U.S. market. The news is सकारात्मक for Lupin but is likely more company-specific than market-wide.

Analysis

Lupin received U.S. FDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis, in both vial and pre-filled syringe formats. The approval covers the same 0.3 mg and 0.5 mg strengths as the reference product, expanding Lupin’s biosimilar portfolio in the U.S. market. The news is सकारात्मक for Lupin but is likely more company-specific than market-wide.